Optimizing Reporting and Outreach for Surveillance and Risk-Reducing Surgeries for Cancer Genetic Predisposition: Findings of a Workshop Organized by the International Cascade Consortium
Year: 2026
Type: article
Abstract: INTRODUCTION: Improving access to genetic testing has increased the number of individuals identified with cancer genetic predisposition. Hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) are key examples of high-risk hereditary cancer syndromes. Ensuring that carriers of germline pathogenic/likely pathogenic variants (GPVs) receive evidence-based risk counseling, surveillance and risk-reducing interventions remains a global challenge. Variations in implementation and reporting of international guidelines across healthcare systems contribute to this problem. METHODS: An international workshop on cancer genetic care, held from March 12 to March 15, 2025, in Switzerland, brought together 40 experts on this topic from 10 countries. The workshop combined evidence-based presentations with expert-led discussions and considered novel strategies, which were synthesized in key discussion points. RESULTS: Participants highlighted major inconsistencies in reporting age of initiation and uptake of surveillance, follow-up intervals, and uptake of risk-reducing interventions for carriers of GPVs associated with genetic predisposition to cancer between and within countries. These differences are due to variations in available technology, insurance coverage, and sociocultural attitudes that shape national clinical guidelines. Participants emphasized the need for a standardized approach for reporting surveillance practices, including clear definitions of gene-specific recommendations, timing of follow-up, and alternatives when ideal resources are limited. In addition to these reporting issues, participants also noted the need for sustained outreach for lifelong follow-up surveillance of GPV carriers through digital as well as low-tech approaches. CONCLUSION: Standardized reporting of surveillance and risk-reducing practices across countries may improve the quality and comparability of data in cancer genetic predisposition, reveal gaps in genetic care, and inform outreach strategies for engaging GPV carriers in lifelong cancer risk management.
Source: Public Health Genomics
DOI: 10.1159/000553075
Authors: Bardha Citaku-Qerimi, Hanna Yttring, Sofia E. Andersson, Margreet G.E.M. Ausems, Sivia Barnoy, Maria Caiata-Zufferey, Deborah Cragun, Efrat Dagan, Marleah Dean, Katrina R. Ellis, Lea Godino, Senada Hajdarevic, Ylva Heyman, Sue Kim, Fred H. Menko, Carla Pedrazzani, Helle V. Petersen, Amicia Phillips, Susanna Pusa, Charité N. Ricker, Anna Rosén, Meghan Underhill, Pamela Ganschow, Elena M. Stoffel, D. Gareth Evans, Joanne Ngeow, Tuya Pal, Heather Hampel, Maria C. Katapodi
Institutions: University of Basel, Lund University, Umeå University, Utrecht University, University Medical Center Utrecht, Tel Aviv University, University of Applied Sciences and Arts of Southern Switzerland, University of South Florida, University of Haifa, University of Michigan, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna, Yonsei University, The Netherlands Cancer Institute, Zealand University Hospital, University of Exeter, University of Southern California, University of Rochester, University of Illinois Chicago, University of Manchester, Nanyang Technological University, Vanderbilt University, Vanderbilt-Ingram Cancer Center, City Of Hope National Medical Center
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W7166513684
FWCI:
Cites:
Cited by:
Related to: